TREM1 and colitis: Safety Profile of GF9: Preclinical investigations in murine models of sepsis, colitis, and liver injury demonstrated that GF9 effectively inhibits TREM-1/DAP12 interactions, thereby attenuating excessive cytokine release while maintaining phagocytic capacity and bacterial clearance.